Nasdaq for Samsung
Print Edition
SOUTH Korea’s Samsung will make its first entry into US stock markets next year with the listing of a biotechnology affiliate, a company official said yesterday.
The listing of Samsung Bioepis on Nasdaq is aimed at securing funds for investment in the field of biosimilars — a new breed of drugs that mimic the effects of far more costly biologic drugs made from living cells.
“With an underwriter already designated, preparations are under way for the public stock listing of Bioepis in the first half of next year,” the Samsung official said.
Bioepis will be the first Samsung affiliate to list in the US.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
